Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

This publication has 27 references indexed in Scilit:

• Telaprevir for Previously Treated Chronic HCV Infection
  New England Journal of Medicine, 2010
• 85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV)
  Journal of Hepatology, 2009
• Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
  New England Journal of Medicine, 2009
• The global burden of hepatitis C
  Liver International, 2009
• Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
  Antimicrobial Agents and Chemotherapy, 2008
• Changing trends in hepatitis C–related mortality in the United States, 1995‐2004†‡
  Hepatology, 2007
• Inhibition of Hepatitis C Replicon RNA Synthesis by β-D-2′-deoxy-2′-fluoro-2′-C-Methylcytidine: A Specific Inhibitor of Hepatitis C Virus Replication
  Antiviral Chemistry and Chemotherapy, 2006
• Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study
  Gastroenterology, 2004
• Projecting future complications of chronic hepatitis C in the United States
  Liver Transplantation, 2003
• Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C
  Annals of Internal Medicine, 2000